top of page

As an Impact Fund:  to hold ourselves and HIC ‘s portfolio companies to a hig

  • ​

Industry News

HIC team members are thought leaders at the intersection of healthcare innovation, pediatrics and venture capital. 

iStock-462586235.jpg

Characterizing the tumor microenvironment in rare renal cancer histological types

VF: Naoise Synnott

iStock-462586235.jpg

Assessment of executive function declines in presymptomatic and mildly symptomatic familial frontotemporal dementia: NIH-EXAMINER as a potential clinical trial endpoint

VF: Reilly Dever

iStock-462586235.jpg

COTI-2 reactivates mutant p53 and inhibits growth of triple-negative breast cancer cells

VF: Naoise Synnott

iStock-462586235.jpg

The Epithelial to Mesenchymal Transition Promotes Glutamine Independence by Suppressing GLS2 Expression

VF: Esmeralda Ramirez-Peña 

iStock-462586235.jpg

Mutant p53: a novel target for the treatment of patients with triple-negative breast cancer?

VF: Naoise Synnott

iStock-462586235.jpg

Distinguishing mechanisms underlying
EMT tristability

VF: Esmeralda Ramirez-Peña 

Fireside Chat Series:
Featuring Alex Lebeaut, MD and Naoise Synnott, PhD
I-ACT for Children and
Health Innovation Capital

bottom of page